sunny.png
Sunday August 1st, 2021 1:07PM

Strong Q2 from J&J as pandemic-hit sales, profit recover

By The Associated Press
Related Articles
  Contact Editor

Johnson & Johnson’s second-quarter profit soared 73%, thanks to strong sales growth across all of its businesses as hospitals and the rest of the health care industry continued recovering from the coronavirus pandemic's impact.

The health care giant handily topped Wall Street expectations and hiked its 2021 sales and profit forecasts sharply..

The world’s biggest maker of health care products on Wednesday reported second-quarter net income of $6.28 billion, or $2.35 per share, up from $3.63 billion, or $1.36 per share, a year earlier.

Adjusted income came to $6.63 billion, or $2.48 per share, blowing past Wall Street projections for $2.28 per share.

Revenue totaled a whopping $23.31 billion, up 27.1% from 2020's second quarter.

The one weak spot was dismal sales of J&J's COVID-19 vaccine, which brought in just $164 million in the quarter and $264 million so far this year.

The vaccine has been plagued by concerns about some very rare side effects and the shutdown of the Maryland factory of J&J's U.S. contract manufacturer, Emergent BioSolutions, due to contamination problems that led to tens of millions of vaccine doses having to be trashed. It’s unclear when — or if — the U.S. Food and Drug Administration will allow the factory to resume production, which was halted in mid-April.

J&J has the only authorized vaccine that only requires one shot, so it had been expected to play a huge role in vaccinating people in rural areas and developing countries. Instead, the company has fallen far short of its supply commitments to the U.S., other governments and a World Health Organization-backed program to get affordable vaccines to poor and middle-income countries. However, J&J recently got approval to make more vaccine doses at its newly expanded factory in the Netherlands.

Company executives said they expect total 2021 COVID-19 vaccine sales of roughly $2.5 billion, mostly in the fourth quarter.

“We hope this will be the start of what we expect to become a vibrant vaccine business over time,” including vaccines it's developing for HIV, sepsis and respiratory syncytial virus, Jennifer Taubert, head of the prescription medicine business, told analysts on a call to discuss the quarter’s results.

Johnson & Johnson noted recent studies show the vaccine works well against coronavirus variants and protects people for at least eight months. The company said it's selling its vaccine on a nonprofit basis, for $5 to $8 per dose.

J&J, based in New Brunswick, New Jersey, said foreign sales jumped 29.5% to $11.39 billion, while U.S. sales rose 24.9% to $11.92 billion.

J&J’s medical device and diagnostics division had been a laggard amid a lengthy restructuring and the pandemic leading people to delay scheduled surgeries and other care. It turned in the best performance in the quarter, with revenue jumping 62.7% to $6.98 billion.

Still, the company warned that some U.S. hospital systems are again delaying elective procedures as infections and hospitalizations increase amid the latest surge, caused by the highly transmissible delta variant.

The maker of cancer drugs Darzalex and Imbruvica reported that prescription drug sales, long the company’s main growth driver, rose 17.2% to $12.6 billion.

Sales of consumer health products like Tylenol and Band-Aids, which have been buoyed during the pandemic by medicine cabinet stocking and an increased focus on wellness, climbed 13.3% to $3.74 billion.

“The company’s earnings growth has accelerated, driven by newly launched drugs and a decreasing impact from patent losses,” Edward Jones analyst Ashtyn Evans wrote to investors, adding that the current stock price doesn’t fully reflect the growth of J&J’s new products.

Evans, noting recent headlines about lawsuits over J&J’s talc products and a potential $5 billion settlement with states over its sales of opioid painkillers Duragesic and Nucynta, said progress in ending that litigation should reduce uncertainty about the stock.

Overall sales had a 4.1% benefit from favorable currency exchange rates. During the quarter, J&J's effective tax rate declined to 5.8% and the company paid shareholders $2.8 billion in dividends.

During the quarter, the FDA approved J&J’s Rybrevant, the first targeted treatment for non-small cell lung cancer that has certain genetic mutations.

Johnson & Johnson said it expects adjusted full-year earnings in the range of $9.60 to $9.70 per share, up from its April forecast of $9.42 to $9.57. It expects revenue in the range of $93.8 billion to $94.6 billion, up from $90.6 billion to $91.6 billion.

In afternoon trading, J&J shares rose 82 cents to $169.27.

___

Follow Linda A. Johnson on Twitter: @LindaJ_on Pharma

  • Associated Categories: Associated Press (AP), AP Business, AP Business - Corporate News, AP Business - Industries, AP Business - Health Care
© Copyright 2021 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Coke sales surge in Q2 as re-openings gain momentum
Coca-Cola's sales are rebounding faster than expected as the impact of the pandemic abates
11:55AM ( 8 minutes ago )
Infrastructure bill expected to fail first test vote
Senate Republicans are poised to reject an effort to begin debate on a bipartisan infrastructure deal that senators brokered with President Joe Biden
11:54AM ( 10 minutes ago )
Strong Q2 from J&J as pandemic-hit sales, profit recover
Johnson & Johnson’s second-quarter profit soared 73%, thanks to strong sales growth, particularly in its medical device and diagnostics segment, as hospitals and the health care industry as a whole continue recovering from the coronavirus pandemic
11:47AM ( 16 minutes ago )
Associated Press (AP)
A small victory: Used-car prices slip from dizzy heights
For months, anyone who wandered onto a dealer lot to look for a used car could be forgiven for doing a double take — and then wandering right off the lot
11:15AM ( 49 minutes ago )
German Cabinet approves some $472 million in first flood aid
Germany’s Cabinet has approved a roughly 400 million-euro ($472 million) package of immediate aid for flood victims and vowed to get started quickly on rebuilding devastated areas
10:43AM ( 1 hour ago )
Agency eyes 'right-to-repair' rules to aid consumers, shops
Consumers would be freer to repair their broken cellphones, computers, videogame consoles and even tractors themselves or to use independent repair shops under changes eyed by federal regulators that target manufacturers’ restrictions
10:36AM ( 1 hour ago )
AP Business
Stocks start higher on Wall Street as more earnings roll in
Stocks are opening higher on Wall Street as the market continues to recover from a sharp drop at the beginning of the week
9:46AM ( 2 hours ago )
Strong Q2 from J&J as pandemic-hit sales, profit recover
Johnson & Johnson’s second-quarter profit soared 73%, thanks to strong sales growth, particularly in its medical device and diagnostics segment, as hospitals and the health care industry as a whole continue recovering from the coronavirus pandemic
8:30AM ( 3 hours ago )
No. 2 US diplomat Sherman to visit China as tensions soar
Deputy Secretary of State Wendy Sherman will travel to China this weekend on a visit that comes as tensions between Washington and Beijing soar on multiple fronts
7:57AM ( 4 hours ago )
AP Business - Corporate News
Record-high electricity bills draw criticism to Spain's govt
Spanish consumers are fretting over record-high power prices just as high summer temperatures are keeping air conditioning and cooling systems operating at full capacity
9:49AM ( 2 hours ago )
Floods fuel climate debate in Germany's election campaign
Germany's deadliest inland floods in living memory have propelled the issue of climate change to the fore of the country's election campaign
8:25AM ( 3 hours ago )
The Latest: South Korea hits pandemic high for daily cases
South Korea has reported a new daily high for coronavirus cases, putting pressure on authorities to extend their toughest distancing rules
10:19PM ( 13 hours ago )
AP Business - Industries
The Latest: Fauci, Paul trade charges of lying about virus
A recurring clash between the government’s top infectious disease doctor and a U.S. senator has erupted again on Capitol Hill, with each accusing the other of lying
1:11PM ( 22 hours ago )
The Latest: Britain hits most daily virus deaths in 4 months
Britain has recorded its highest daily number of coronavirus-related deaths in four months, following a spike in infections amid the spread of the delta variant and lifting of lockdown restrictions
12:00PM ( 1 day ago )
The Latest: CDC: Delta variant accounts for 83% of US cases
Health officials say the delta variant of the coronavirus continues to surge and accounts for an estimated 83% of U.S. COVID-19 cases
10:36AM ( 1 day ago )
AP Business - Health Care
Coke sales surge in Q2 as re-openings gain momentum
Coca-Cola's sales are rebounding faster than expected as the impact of the pandemic abates
11:55AM ( 9 minutes ago )
Infrastructure bill expected to fail first test vote
Senate Republicans are poised to reject an effort to begin debate on a bipartisan infrastructure deal that senators brokered with President Joe Biden
11:54AM ( 10 minutes ago )
Rare pink water bird lands in Michigan, delighting public
Bird lovers are traveling to a stream in southeastern Michigan to see a rare creature with pink feathers and a long bill
11:46AM ( 18 minutes ago )
Massive wildfires in US West bring haze to East Coast
Wildfires in the U.S. West are creating hazy skies as far away as New York as the massive infernos spew smoke and ash into the air
11:41AM ( 22 minutes ago )
Sex Pistols singer calls TV show 'nonsense' in songs dispute
Former Sex Pistols singer John Lydon says he is “heart and soul” against letting the band’s songs be used in an upcoming television drama series about the pioneering punk outfit
11:39AM ( 25 minutes ago )